Eaton Alexander M, Gordon Gabriel M, Booth Dave, Wafapoor Hussein, Avery Robert L
Ophthalmic Surg Lasers Imaging Retina. 2014 May-Jun;45(3):232-8. doi: 10.3928/23258160-20140430-01. Epub 2014 May 12.
Determine whether the new dexamethasone intravitreal implant (Ozurdex; Allergan, Irvine, CA) injector needle design can reduce the force needed for insertion when compared to the original needle design.
In vitro testing assessed the force required for insertion from five new-design and five old-design Ozurdex needles on a synthetic test medium and explanted porcine eyes. Maximum penetration force was measured in grams-force, while the total work of the needle was measured in joules.
The new design required 29% and 68% less overall work to perform an injection in the synthetic medium (P = .0002) and porcine eyes (P = .009), respectively. The maximum force required to insert the new needle was 25% and 61% that of the old needle in the synthetic medium (P = .001) and porcine eyes (P = .007), respectively.
The new needle design significantly reduces the force and work needed for insertion, which should improve physician control as well as patient safety and comfort.
确定与原始针头设计相比，新型地塞米松玻璃体内植入剂（Ozurdex；爱尔康公司，加利福尼亚州欧文市）注射器针头设计是否能降低插入所需的力。
体外测试评估了五支新型设计和五支旧型设计的Ozurdex针头在合成测试介质和摘除的猪眼上插入所需的力。最大穿透力以克力为单位测量，而针头的总功以焦耳为单位测量。
在合成介质（P = .0002）和猪眼（P = .009）中进行注射时，新型设计所需的总功分别减少了29%和68%。在合成介质（P = .001）和猪眼中，插入新型针头所需的最大力分别为旧型针头的25%和61%（P = .007）。
新型针头设计显著降低了插入所需的力和功，这应能改善医生的操作控制以及患者的安全性和舒适度。
